the impact of ighv mutational status in treatment decisions in cll
Published 1 year ago • 396 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
1:14
cll: ighv mutational status
-
1:11
the prognostic value of ighv mutational status with continuous vs time-limited therapy in cll
-
2:08
disease characteristics impacting treatment decisions in cll
-
1:44
ibrutinib and fcr in cll irrespective of ighv mutation status
-
2:08
the differences in outcomes and treatment in cll patients with mutated and unmutated ighv
-
2:34
the impact of gene mutations on prognosis in cll
-
30:04
yunhe li: segmentation of lymphoma in pet/ct images
-
8:40
chronic lymphocytic leukemia( cll)
-
7:29
what cll tests are essential and how do results impact treatment and prognosis?
-
1:13
molecular mrd as a prognostic marker for aml patients with mutated cebpa
-
2:11
genetic testing to risk stratify a patient with cll and aid in treatment decisions
-
1:04
defining high-risk cll: known and emerging mutations
-
0:53
clinical significance of ig gene mutations in cll
-
5:21
examples of biology informing treatment decisions in cll
-
3:55
the origins of mutated and unmutated cll
-
2:32
ifcg for first-line treatment of ighv-mutated cll
-
2:59
reducing the risks of chemotherapy in ighv-mutated cll
-
1:12
the reduced prognostic impact of the cll-ipi in the new era of targeted agents
-
1:42
the future of cll treatment: aiming for long-lasting remission
-
1:12
the importance of targeting proliferating and quiescent cells in cll
-
4:31
the impact of high and low burden tp53 mutations on risk and treatment decision in cll